ErbB2 and fatty acid synthase (FAS) expression in 102 squamous cell carcinomas of the tongue: Correlation with clinical outcomes

Oral Oncology

Volumn 44, Issue 5, 2008, Pages 484-490

  Silva, Sabrina D ^a   Perez, Danyel E ^a   Alves, Fabio A ^b   Nishimoto, Inês N ^b   Pinto, Clóvis A L ^b   Kowalski, Luiz P ^b   Graner, Edgard ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

ErbB2; Fatty acid synthase; Ki 67; Oral cancer; Oral squamous cell carcinoma; Prognostic factor; Survival analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; KI 67 ANTIGEN; PARAFFIN;

ADULT; ARTICLE; BIOSYNTHESIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; KERATINOCYTE; LOG RANK TEST; MALE; MEDICAL RECORD; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STAINING; TONGUE CARCINOMA;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TONGUE NEOPLASMS; TREATMENT OUTCOME;

EID: 42949097680     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.06.008     Document Type: Article

References (54)

1. Popescu N.C., King C.R., and Kraus M.H. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4 3 (1989) 362-366
2. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 13 (2000) 3159-3167
3. Schechter A.L., Hung M.C., Vaidyanathan L., Weinberg R.A., Yang-Feng T.L., Francke U., et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229 4717 (1985) 976-978
4. Bargmann C.I., Hung M.-C., and Weinberg R.A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319 (1986) 226-230
5. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
6. Mimura K., Kono K., Hanawa M., Mitsui F., Sugai H., Miyagawa N., et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Brit J Cancer 92 7 (2005) 1253-1260
7. Albuquerque Jr. R.L., Miguel M.C., Costa A.L., and Souza L.B. Correlation of c-erbB-2 and S-100 expression with the malignancy grading and anatomical site in oral squamous cell carcinoma. Int J Exp Pathol 84 6 (2003) 259-265
8. Pinto-de-Sousa J., David L., Almeida R., Leitao D., Preto J.R., Seixas M., et al. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 10 4 (2002) 247-256
9. Ueda S., Ogata S., Tsuda H., Kawarabayashi N., Kimura M., Sugiura Y., et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29 1 (2004) 1-8
10. Eissa S., Ali H.S., Al Tonsi A.H., Zaglol A., and El Ahmady O. HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochem 38 2 (2005) 142-148
11. Cheng C.M., Tsuneyama K., Matsui K., Takahashi H., Ishizawa S., and Takano Y. Cytoplasmic expression of c-erbB2 in non-small cell lung cancers. Virchows Arch 446 6 (2005) 596-603
12. Khan A.N., Yang W., Seifalian A.M., and Winslet M.C. HER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus. Brit J Cancer 94 8 (2006) 1213-1215
13. Metges J.P., Gibault L., Conan-Charlet V., Lozac'h P., Robaszkiewicz M., and Bessaguet C. Reply: Her2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus?. Brit J Cancer 94 8 (2006) 1214-1215
14. Brand F.X., Ravanel N., Gauchez A.S., Pasquier D., Payan R., Fagret D., et al. Prospect for anti-HER2 receptor therapy in breast cancer. Anticancer Res 26 1B (2006) 463-470
15. Pritchard K.I., Shepherd L.E., O'Malley F.P., Andrulis I.L., Tu D., Bramwell V.H., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. New Engl J Med 354 20 (2006) 2103-2111
16. Eccles S.A. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6 4 (2001) 393-406
17. Menard S., Fortis S., Castiglioni F., Agresti R., and Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 61 2 (2001) 67-72
18. Yeon C.H., and Pegram M.D. Anti-erbB-2 antibody trastuzumab in the treatment of HER-2-amplified breast cancer. Invest New Drugs 23 (2005) 391-409
19. Kumar-Sinha C., Ignatoski K.W., Lippman M.E., Ethier S.P., and Chinnaiyan A.M. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63 1 (2003) 132-139
20. Baron A., Migita T., Tang D., and Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer?. J Cell Biochem 91 1 (2004) 47-53
21. Jayakumar A., Tai M.H., Huang W.Y., al-Feel W., Hsu M., Abu-Elheiga L., et al. Human fatty acid synthase: properties and molecular cloning. Proc Natl Acad Sci 92 19 (1995) 8695-8699
22. Innocenzi D., Alo P.L., Balzani A., Sebastiani V., Silipo V., La Torre G., et al. Fatty acid synthase expression in melanoma. J Cutan Pathol 30 1 (2003) 23-28
23. Takahiro T., Shinichi K., and Toshimitsu S. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 9 6 (2003) 2204-2212
24. Alo P.L., Visca P., Framarino M.L., Botti C., Monaco S., Sebastiani V., et al. Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 7 6 (2000) 1383-1388
25. Kusakabe T., Nashimoto A., Honma K., and Suzuki T. Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology 40 1 (2002) 71-79
26. Silva S.D., Agostini M., Nishimoto I.N., Coletta R.D., Alves F.A., Lopes M.A., et al. Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. Oral Oncol 40 7 (2004) 688-696
27. Agostini M., Silva S.D., Zecchin K.G., Coletta R.D., Jorge J., Loda M., et al. Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells. Oral Oncol 40 7 (2004) 728-735
28. Krontiras H., Roye G.D., Beenken S.E., Myers R.B., Mayo M.S., Peters G.E., et al. Fatty acid synthase expression is increased in neoplastic lesions of the oral tongue. Head Neck 21 4 (1999) 325-329
29. Menendez J.A., Lupu R., and Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 18 6 (2005) 375-385
30. Menendez J.A., Mehmi I., Verma V.A., Teng P.K., and Lupu R. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinogen 41 3 (2004) 164-178
31. Furuya Y., Akimoto S., Yasuda K., and Ito H. Apoptosis in androgen independent prostate cell line induced by inhibition of fatty acid synthesis. Anticancer Res 17 6D (1997) 4589-4593
32. Pizer E.S., Chrest F.J., DiGiuseppe J.A., and Han W.F. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 58 20 (1998) 4611-4615
33. Li J.N., Gorospe M., Chrest F.J., Kumaravel T.S., Evans M.K., Han W.F., et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 61 4 (2001) 1493-1499
34. Brusselmans K., De Schrijver E., Verhoeven G., and Swinnen J.V. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65 15 (2005) 6719-6725
35. Menendez J.A., Vellon L., and Lupu R. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 16 8 (2005) 1253-1267
36. Kridel S.J., Axelrod F., Rozenkrantz N., and Smith J.W. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64 6 (2004) 2070-2075
37. Pizer E.S., Thupari J., Han W.F., Pinn M.L., Chrest F.J., Frehywot G.L., et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60 2 (2000) 213-218
38. Menendez J.A., Vellon L., Mehmi I., Oza B.P., Ropero S., Colomer R., et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 101 29 (2004) 10715-10720
39. Wahi P.N., Cohen B., Luthra Usha K., and Torloni H. Histological typing of oral and oropharyngeal tumours (1971), World Health Organization, Geneva p. 28
40. Xia W., Lau Y.K., Zhang H.Z., Liu A.R., Li L., Kiyokawa N., et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 3 1 (1997) 3-9
41. Xia W., Lau Y.K., Zhang H.Z., Xiao F.Y., Johnston D.A., Liu A.R., et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5 12 (1999) 4164-4174
42. Werkmeister R., Brandt B., and Joos U. Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 36 1 (2000) 100-105
43. Bei R., Pompa G., Vitolo D., Moriconi E., Ciocci L., Quaranta M., et al. Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol 195 3 (2001) 343-348
44. Khan A.J., King B.L., Smith B.D., Smith G.L., DiGiovanna M.P., Carter D., et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 8 2 (2002) 540-548
45. Khademi B., Shirazi F.M., Vasei M., Doroudchi M., Gandomi B., Modjtahedi H., et al. The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett 184 2 (2002) 223-230
46. Half E., Broaddus R., Danenberg K.D., Danenberg P.V., Ayers G.D., and Sinicrope F.A. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 108 4 (2004) 540-548
47. Alo P.L., Visca P., Marci A., Mangoni A., Botti C., and Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77 3 (1996) 474-482
48. Gansler T.S., Hardman III W., Hunt D.A., Schaffel S., and Hennigar R.A. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28 6 (1997) 686-692
49. Shurbaji M.S., Kalbfleisch J.H., and Thurmond T.S. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 27 9 (1996) 917-921
50. Visca P., Sebastiani V., Botti C., Diodoro M.G., Lasagni R.P., Romagnoli F., et al. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res 24 6 (2004) 4169-4173
51. Sebastiani V., Visca P., Botti C., Santeusanio G., Galati G.M., Piccini V., et al. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol Oncol 92 1 (2004) 101-105
52. Visca P., Sebastiani V., Pizer E.S., Botti C., De Carli P., Filippi S., et al. Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma. Anticancer Res 23 1A (2003) 335-339
53. Alo P.L., Visca P., Trombetta G., Mangoni A., Lenti L., Monaco S., et al. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85 1 (1999) 35-40
54. Zhang Y., Guo C., and Yu G. A pilot study of fatty acid metabolism in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 34 1 (2005) 78-81